Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zapping the brain with microcurrents may curb cravings — a trial puts it to the test

NCT ID NCT07737652

Symptom relief Sponsor: University of Alabama, Tuscaloosa Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This pilot trial tests whether adding microcurrent neurofeedback (MCN) to standard residential treatment helps adults with substance use disorder more than standard care alone. MCN uses scalp sensors to deliver barely perceptible electrical pulses tailored to each person's brain activity. Researchers will measure changes in cravings, depression, anxiety, and PTSD symptoms over 12 weeks. The study also checks whether MCN is practical to use in a residential treatment setting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a noninvasive device that delivers low-intensity electrical pulses to the scalp, called microcurrent neurofeedback (IASIS MCN)
What this could lead to
If it works, this could offer a drug-free way to reduce cravings and improve mental health during substance use treatment.
What could go wrong
This is a small pilot study, so results may not apply broadly. The device's effects on cravings and mood are still uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

61 people

The number who actually took part.

Started

Oct 2025

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age 18 to 65 years at enrollment Current substance use disorder (SUD) diagnosis of any substance type Active enrollment in a residential SUD treatment program, with a minimum of 4 weeks of program enrollment completed prior to study enrollment (stabilization period) Medically stable English proficiency Willingness and ability to provide written informed consent Exclusion Criteria: Severe cognitive impairment Active psychosis or acute psychiatric instability Neurological disorder likely to interfere with neurofeedback Concurrent enrollment in another interventional study Current receipt of another form of neurofeedback therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anxiety are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety anxiety disorder Depression depressive disorder opiate dependence post-traumatic stress disorder substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anxiety Depression Post-traumatic stress disorder Substance use disorder (SUD)

Contacts and locations

Locations

  • Capstone College of Nursing, 650 University Blvd, 35401 Tuscaloosa

    Tuscaloosa, Alabama, 35401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.